| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/19/2012 | WO2012006965A1 Tablet with improved comprehensive performance and preparation method therefor |
| 01/19/2012 | WO2012006963A1 Polymer reinforcing agent in controlled release preparation |
| 01/19/2012 | WO2012006961A1 Controlled release formulation |
| 01/19/2012 | WO2012006959A1 Controlled release preparation |
| 01/19/2012 | WO2012006956A1 Insulin-lipid complex, preparation method therefor, and preparation thereof |
| 01/19/2012 | WO2012006938A1 Pharmaceutical composition capable of targeted release of trace element, and preparation method and application of pharmaceutical composition |
| 01/19/2012 | WO2012006698A1 A biocomposite, uses thereof, process for producing same and a method for controlled release of an antimicrobial substance |
| 01/19/2012 | WO2012006683A1 Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists |
| 01/19/2012 | WO2011153493A3 Biodegradable lipids for the delivery of active agents |
| 01/19/2012 | WO2011141708A3 New particles of tetracyclines and protecting agent |
| 01/19/2012 | WO2011126910A3 Compositions and methods for the treatment of somatosensory disorders |
| 01/19/2012 | WO2011126537A3 Oral adhering compositions that apply rhizophora mangle extract in the mouth |
| 01/19/2012 | WO2011117391A3 Novel composition for treatment of essential thrombocythemia |
| 01/19/2012 | WO2011112801A3 Dual function product |
| 01/19/2012 | WO2011112799A3 Structured non-aqueous gel-form carrier composition |
| 01/19/2012 | WO2011110694A3 Micelle compositions and process for the preparation thereof |
| 01/19/2012 | WO2011109494A3 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/19/2012 | WO2011109106A3 Immunogenic compositions against human progastrin peptides |
| 01/19/2012 | WO2011106424A3 Feline stimulant and method of manufacture |
| 01/19/2012 | WO2011106376A3 Use of microvesicles in the treatment of medical conditions |
| 01/19/2012 | WO2011106309A3 Materials and methods for mri contrast agents and drug delivery |
| 01/19/2012 | WO2011101863A3 Extended release pharmaceutical compositions of lacosamide |
| 01/19/2012 | WO2011084618A3 Compositions and methods for oral drug delivery |
| 01/19/2012 | WO2011063774A3 Pectin complexes of steroids and pharmaceutical compositions based thereon |
| 01/19/2012 | WO2011060945A3 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
| 01/19/2012 | WO2011037953A3 Implant devices having varying bioactive agent loading configurations |
| 01/19/2012 | WO2011034604A9 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 01/19/2012 | WO2011016881A4 An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation |
| 01/19/2012 | WO2011009852A3 Topical pharmaceutical composition including rel-n- [6 - [ (2r, 6s) - 2, 6 - dimethyl - 4 -morpholinyl] -3 - pyridinyl] - 2 -methyl -41 (trifluoromethoxy) - [1,1' -biphenyl] - 3 - carboxamide |
| 01/19/2012 | WO2011003853A3 Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| 01/19/2012 | WO2010140007A9 Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug |
| 01/19/2012 | WO2010136952A3 Self-microemulsifying mitotane composition |
| 01/19/2012 | WO2010103374A9 Oily suspension containing probiotic bacteria for paediatric uses |
| 01/19/2012 | US20120016491 Laminate sheet articles for tissue regeneration |
| 01/19/2012 | US20120016475 Degradable composite |
| 01/19/2012 | US20120016467 Polymer-based, sustained release drug delivery system |
| 01/19/2012 | US20120016338 Chemoablation of tissue using biodegradable, solid salt dosage forms |
| 01/19/2012 | US20120016311 Drug Delivery Catheters That Attach to Tissue and Methods for Their Use |
| 01/19/2012 | US20120016123 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 01/19/2012 | US20120016024 Water-In-Oil Emulsion Composition |
| 01/19/2012 | US20120015996 Antifungal medicinal compositions |
| 01/19/2012 | US20120015971 Ophthalmic composition comprising ascomycin |
| 01/19/2012 | US20120015331 Scaffold |
| 01/19/2012 | US20120015039 Sustained release of nutrients in vivo |
| 01/19/2012 | US20120015038 Enterically coated cysteamine, cystamine and derivatives thereof |
| 01/19/2012 | US20120015037 Functionalized nanoparticle, method for preparing the same and application thereof |
| 01/19/2012 | US20120015036 Process For The Manufacture Of A Pharmaceutical Product |
| 01/19/2012 | US20120015035 Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists |
| 01/19/2012 | US20120015034 Temperature sensitive polymers |
| 01/19/2012 | US20120015033 Antisense compositions and methods of making and using same |
| 01/19/2012 | US20120015032 Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
| 01/19/2012 | US20120015031 Novel gastro-retentive dosage forms |
| 01/19/2012 | US20120015030 Modified release formulations containing drug-ion exchange resin complexes |
| 01/19/2012 | US20120015029 Direct compression formulation and process |
| 01/19/2012 | US20120015028 Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof |
| 01/19/2012 | US20120015027 F, G, H, I and K Crystal Forms of Imatinib Mesylate |
| 01/19/2012 | US20120015026 Pharmaceutical composition containing a drug and sirna |
| 01/19/2012 | US20120015025 Cholestanol derivative for combined use |
| 01/19/2012 | US20120015024 Methods for treating tweak-related conditions |
| 01/19/2012 | US20120015023 Treatment of tumors prostate with arsonoliposomes |
| 01/19/2012 | US20120015022 Biodegradable wound care products with biocompatible artificial skin treatment |
| 01/19/2012 | US20120015021 Anti-appetite adhesive compositions |
| 01/19/2012 | US20120015020 Biodegradable drug or other active delivery system |
| 01/19/2012 | US20120015014 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 01/19/2012 | US20120015010 Compositions Comprising Pigment Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same |
| 01/19/2012 | US20120015008 Anti-adhesive composition, solid preparation, and process for producing the same |
| 01/19/2012 | US20120015007 Abuse resistant formula |
| 01/19/2012 | US20120015006 Flowable collagen material for dural closure |
| 01/19/2012 | US20120015005 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| 01/19/2012 | US20120015004 Encapsulated salts and use in high acid beverages |
| 01/19/2012 | US20120015003 Layered Scaffold Suitable for Osteochondral Repair |
| 01/19/2012 | US20120015001 Methods of treating thyroid eye disease |
| 01/19/2012 | US20120015000 Malaria vaccine of self-assembling polypeptide nanoparticles |
| 01/19/2012 | US20120014999 Diketopiperazine Microparticles with Defined Specific Surface Areas |
| 01/19/2012 | US20120014991 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces |
| 01/19/2012 | US20120014882 Skin care compositions |
| 01/19/2012 | US20120014878 Synthesis of Oligonucleotide Mediated Gold Core- Silver Shell Nanoparticles |
| 01/19/2012 | US20120012499 Tablet formulation |
| 01/19/2012 | US20120012123 Compositions, articles and methods for preventing or reducing tobacco-associated damage |
| 01/19/2012 | CA2805728A1 Microparticles comprising a small heat-shock protein |
| 01/19/2012 | CA2805724A1 Organic compounds |
| 01/19/2012 | CA2805700A1 Pharmaceutical compositions |
| 01/19/2012 | CA2805645A1 C-met modulator pharmaceutical compositions |
| 01/19/2012 | CA2805643A1 Targeted nanoparticles for cancer and other disorders |
| 01/19/2012 | CA2805631A1 Drug delivery medical device |
| 01/19/2012 | CA2805356A1 Composition for the treatment of superficial lesions |
| 01/19/2012 | CA2805325A1 Insulin-lipid complex, preparation method therefor, and preparation thereof |
| 01/19/2012 | CA2805228A1 A liquid formulation of long-acting human growth hormone conjugate |
| 01/19/2012 | CA2805222A1 Method and formulations for treating sialic acid deficiencies |
| 01/19/2012 | CA2805203A1 Formulations of 14 - epi -analogues of vitamin d |
| 01/19/2012 | CA2805198A1 Formulations of 14 - epi - analogues of vitamin d and cmc |
| 01/19/2012 | CA2805171A1 Parenteral formulations of elacytarabine derivatives |
| 01/19/2012 | CA2804962A1 Patch for treating skin deseases and alleviating symptoms of skin diseases involving education of blood proteins |
| 01/19/2012 | CA2804697A1 Formulation comprising a type b lantibiotic |
| 01/19/2012 | CA2803471A1 Aqueous composition comprising bromhexine |
| 01/19/2012 | CA2803242A1 Backing having three-layer structure and aqueous patch using the backing |
| 01/19/2012 | CA2803187A1 Treatment of lung infections by administration of tobramycin by aerolisation |
| 01/19/2012 | CA2802404A1 Pharmaceutical form for combating chemical submission of a medicament |
| 01/19/2012 | CA2786570A1 Skin care compositions |
| 01/18/2012 | EP2407536A1 ADP-ribosyl transferase fusion variant proteins |